Amrad changes name to Zenyth Therapeutics
27 October, 2005 by Ruth BeranMelbourne-based Amrad (ASX:AML) will now be known as Zenyth Therapeutics, following a vote at the company's AGM today.
Liability report addresses GM concerns
27 October, 2005 by Helen SchullerIndustry peak body AusBiotech has urged crop growers and marketers to throw their support behind GM technology, following the release of a report that found current legal, farming and commercial systems can adequately deal with issues that may arise from the use of the technology.
J&J exec names comms technology as medical driver
26 October, 2005 by Helen SchullerCommunication technology will be a key driver of medical innovation in the future, a senior Johnson & Johnson executive told a Sydney forum this week.
CathRx lists on ASX at a premium
26 October, 2005 by Helen SchullerSydney medical device company CathRx (ASX:CXD)has made a dream debut on the ASX - after opening at AUD$1.11, shares in the company have traded hands today at up to $1.35, a premium of 35 per cent.
Novogen encouraged by cancer drug trials
25 October, 2005 by Graeme O'NeillAustralian pharma Novogen has received further positive news from a US trial of its experimental cancer-resensitising agent phenoxodiol.
First operating revenues for Ventracor
25 October, 2005 by Ruth BeranSydney-based artificial heart company Ventracor (ASX:VCR) will report its first operating revenues of more than $300,000 in the first half of the 2006 financial year.
Metabolic commences phase IIb obesity drug trial
20 October, 2005 by Ruth BeranMelbourne-based Metabolic Pharmaceuticals (ASX:MBP) has started recruiting subjects in a low dose phase IIb clinical trial of its obesity drug AOD9604.
Imugene licenses poultry productivity product to Merial
14 October, 2005 by Helen SchullerSydney animal-health biotech Imugene (ASX:IMU) has finalised an exclusive sub-license agreement granting international livestock health company and Merck-Aventis subsidiary Merial the global rights to develop and sell Imugene's poultry productivity enhancing product.
Peplin obtains positive anti-leukemia results for drug candidate in mouse model
13 October, 2005 by Helen SchullerPeplin (ASX:PEP) has produced positive results from an initial efficacy study of its drug candidate PEP005 IV in a mouse model of acute myeloid leukemia.
Money flows back into Australian biotech stocks: Intersuisse
11 October, 2005 by Ruth BeranCash is finally flowing towards biotechnology and medical device stocks after a long and sustained drought, according to Intersuisse biotechnology index for the quarter ended September 2005.
GM flu-resistant chooks solution to pandemic threat - British scientist
07 October, 2005 by Graeme O'NeillIt would take only four years to completely replace today's farmed chickens with genetically modified breeds fully resistant to infection to avian influenza, according to a visiting British molecular virologist.
pSivida acquires US drug delivery company
04 October, 2005 by Helen SchullerPerth nano-biotech company pSivida (ASX:PSD; NASDAQ:PSDV; Xetra:PSI) has agreed to purchase privately owned US drug delivery company Control Delivery Systems (CDS) for US$104 million (AUD$139 million), as part of its on-going US growth strategy.
Another 'grass roots' campaign gets feisty about GM
04 October, 2005 by Graeme O'NeillCould 'farmer power' force Australian state governments to back down on their moratoria on GM crops? Graeme O'Neill reports.
OPINION: Is it time to redesign animal agriculture?
30 September, 2005 by Shaun CoffeyOn the eve of a leading livestock conference, CSIRO Livestock Industries chief Shaun Coffey looks at why there are more questions than answers in agriculture -- and why scientists need to join in the debate.
INTERVIEW: Turbocharging for growth
29 September, 2005 by Helen SchullerCochlear boss Chris Roberts has spent 30 years at Australia's leading device companies -- but that doesn't mean he has stopped learning, as Helen Schuller discovers.
